Lord Ara Darzi’s review of the NHS highlights why the UK government needs to act now and invest in dementia diagnosis, care and research.

Alzheimer’s Society will be investing £9million into funding three new Doctoral Training Centres designed to support and nurture dementia researchers at the start of their career.

Chief Marketing Officer, Alex Hyde-Smith, explains why a second airing of our advert The Long Goodbye is important to highlight the devastating impact of dementia on people's lives.

The MHRA have approved lecanemab for some people with early-stage Alzheimer’s disease. However NICE does not recommend use on the NHS for any patients.

Alzheimer’s Society responds to the publication of the Memory Services Spotlight Audit 2023-24, conducted by the Royal College of Psychiatrists as part of the National Audit of Dementia.

The updated Lancet Commission study, which was part funded by Alzheimer's Society, has identified two new risk factors for dementia: untreated vision loss and high low-density lipoprotein (LDL)/bad cholesterol.